THZ531

Item no.	HY-103618-25mg
Manufacturer	MedChem Express
CASRN	1702809-17-3
Amount	25 mg
Quantity options	100 mg 10 mMx1 mL 10 mg 1 mg 25 mg 500 ug 50 mg 5 mg
Category	Metabolism Diabetes Inhibitors & Compound Libraries Small Molecules
Type	Inhibitors
Specific against	other
Purity	99.86
Citations	[1]Zhang T, et al. Covalent targeting of remote cysteine residues to develop CDK12 and CDK13 inhibitors. Nat Chem Biol. 2016 Oct;12(10):876-84.
Smiles	ClC(C(C1=CNC2=CC=CC=C12)=N3)=CN=C3N[C@@H]4CCCN(C(C5=CC=C(NC(/C=C/CN(C)C)=O)C=C5)=O)C4
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Alias	1702809-17-3
Shipping Condition	Cool pack
Available
Manufacturer - Type	Reference compound
Manufacturer - Applications	Cancer-Kinase/protease
Manufacturer - Targets	CDK
Shipping Temperature	Blue Ice
Storage Conditions	-20°C, 3 years (Powder)
Molecular Weight	558.07
Product Description	THZ531 is a selective and covalent inhibitor of both CDK12 and CDK13 with IC50s of 158 nM and 69 nM, respectively[1].
Manufacturer - Research Area	Cancer
Solubility	DMSO: 250 mg/mL (ultrasonic)
Manufacturer - Pathway	Cell Cycle/DNA Damage
Isoform	CDK12; CDK13; CDK7; CDK9
Clinical information	No Development Reported

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

HY-103618-25mg-safety-datasheet.pdf